<h4>Background</h4>Brigatinib is a central nervous system-active second-generation anaplastic lymphoma kinase (ALK) inhibitor that targets a broad range of <i>ALK</i> rearrangements in patients with non-small cell lung cancer (NSCLC). This evidence concerns the gene ALK and non-small cell lung carcinoma.